Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2408399 | 0.94 | NPC1 (0.41) | SMN1; SMN2NPC1DRD3LMNAMAPK1 | |
| SCHEMBL2406071 | 0.88 | SMN1; SMN2 (0.45) | SMN1; SMN2HTTALDH1A1KMT2AKDM4E | |
| SCHEMBL2404213 | 0.85 | SIGMAR1 (0.42) | NPC1ALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL12266241 | 0.82 | CYP3A4 (0.47) | DRD3MAPK1ALDH1A1MEN1KMT2A | |
| SCHEMBL12266379 | 0.80 | SMN1; SMN2 (0.50) | SMN1; SMN2DRD3MEN1KMT2AKDM4E | |
| SCHEMBL2408889 | 0.77 | HPGD (0.51) | SMN1; SMN2NPC1DRD3MAPK1ALDH1A1 | |
| SCHEMBL12319130 | 0.75 | SSTR2 (0.43) | — | |
| SCHEMBL13476066 | 0.75 | HPGD (0.49) | SMN1; SMN2NPC1DRD3MAPK1ALDH1A1 | |
| SCHEMBL12271077 | 0.74 | MEN1 (0.48) | SMN1; SMN2ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL12270761 | 0.73 | LYPLA1 (0.48) | DRD3ALDH1A1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853424-B2 | Protein cross-linking inhibitor | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2014-10-07 | — | — | US | disclosed |
| US-20110212919-A1 | PROTEIN CROSS-LINKING INHIBITOR | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212919-A1 | PROTEIN CROSS-LINKING INHIBITOR | BAZ2B, PRMT1, BRIX1 | SMN1; SMN2 4119/4885NPC1 4339/4885KCNA5 3105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.